PDCD1 and neoplasm: Along the same lines, several groups have discovered that a specific subset of PD-1+ cancer-specific T cells (expressing stem cell markers, TCF1 and CXCR5) do expand in response to anti-PD-1 therapy and are largely responsible for controlling the tumor (64–70).